AR043154A1 - Derivados sustituidos con nitrogeno de hexahidro-pirazino[1,2-a] pirimidin-4,7-diona, procedimientos para su preparacion y su uso como medicamentos - Google Patents
Derivados sustituidos con nitrogeno de hexahidro-pirazino[1,2-a] pirimidin-4,7-diona, procedimientos para su preparacion y su uso como medicamentosInfo
- Publication number
- AR043154A1 AR043154A1 ARP040100426A ARP040100426A AR043154A1 AR 043154 A1 AR043154 A1 AR 043154A1 AR P040100426 A ARP040100426 A AR P040100426A AR P040100426 A ARP040100426 A AR P040100426A AR 043154 A1 AR043154 A1 AR 043154A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- alkylene
- coo
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a derivados sustituidos de hexahidro-pirazino [1,2-a]pirimidin-4,7-diona, así como a sus sales de tolerancia fisiológica y derivados de funcionalidad fisiológica. Compuestos adecuados como anoréxicos, para el tratamiento de la adiposidad. Reivindicación 1: Compuestos de la fórmula (1) en la que significan: A: un anillo mono- bi- o espirocíclico de 3 a 12 miembros, que puede contener uno o varios heteroátomos del grupo N, O, y S, y el anillo de 3 a 12 miembros puede presentar otros sustituyentes como F, Cl, Br, NO2, CF3, OCF3, CN, alquilo C1-6, arilo, CON(R11)(R12), N(R13)(R14), OH, O-alquilo C1-6, S-alquilo C1-6, N(R15)CO-alquilo C1-6 o COO-alquilo C1-6; R11, R12, R13, R14, R15, independientemente entre sí, H, alquilo C1-6, heterociclo; n 0,1; m 0,1,2,3,4,5,6; R1 R8, alquilen C1-6-R8, alquenilen C2-6-R9, (SO2)-R8, (SO2)-alquilen C1-6-R8, (SO2)-alquenilen C2-6-R9, (C=O)-R8,(C=O)-alquilen C1-6-R8, (C=O)NH-R8, (C=O)-alquenilen C2-6-R9, (C=O)-NH-alquilen C1-6-R8, (C=O)-NH-alquenilen C2-6-R9, COO-R8, COO-alquilen C1-6-R8, COO-alquenilen C2-6-R9, alquinilen-R9, (alquil C1-4)-heterociclo, en donde los grupos alquileno pueden estar sustituidos con F; R8, R9 independientemente entre sí H, F, Cl, Br, I, OH, CF3, arilo, heterociclo, cicloalquilo C3-8, pudiendo los ciclos o grupos cíclicos estar mono- o hasta trisustituidos con F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-alquilo C1-6, alquilo C1-6. NH2, CON(R11)(R12), N(R13)(R14), SO2-CH3, COOH, COO-alquilo C1-6, CONH2; R2 NH2, NO2, N(R13)(R14), NH-SO2-CH3, NH-SO2-R12, NR11-SO2-R12, N(CO)R11, un heterociclo que contiene N, en donde el heterociclo está ligado a través de un átomo de N, NHCONR11, N(alquil C1-6)N+(alquil C1-4)3; R3, R4, R5 independientemente entre sí H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-alquilo C1-6, O-alcoxi C1-4-alquilo C1-4, S-alquilo C1-6, alquilo C1-6, alquenilo C2-6, cicloalquilo C3-8, O-cicloalquilo C3-8, cicloalquenilo C3-8, O-cicloalquenilo C3-8, alquinilo C2-6, arilo, O-aril-alquilen C1-8-arilo, O-alquilen C1-8-arilo, S-arilo, N(alquil C1-6)2, SO2-CH3, COOH, COO-alquilo C1-6, CO-N(alquilo C1-6)2; R6 H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-alquilo C1-6, O-alcoxi C1-4-alquilo C1-4, S-alquilo C1-6, alquilo C1-6, alquenilo C2-6, cicloalquilo C3-8, O-cicloalquilo C3-8, cicloalquenilo C3-8, O-cicloalquenilo C3-8, alquinilo C2-6, alquilen C0-8-arilo, O-alquilen C0-8-arilo, S-arilo, N(alquilo C1-6)2, SO2-CH3, COOH, COO-alquilo C1-6, CO-N(alquilo C1-6)2; así como sus sales de tolerancia fisiológica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10305885A DE10305885A1 (de) | 2003-02-13 | 2003-02-13 | Substituierte Hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE10349671A DE10349671A1 (de) | 2003-10-24 | 2003-10-24 | Stickstoff substituierte Hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043154A1 true AR043154A1 (es) | 2005-07-20 |
Family
ID=32870333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100426A AR043154A1 (es) | 2003-02-13 | 2004-02-11 | Derivados sustituidos con nitrogeno de hexahidro-pirazino[1,2-a] pirimidin-4,7-diona, procedimientos para su preparacion y su uso como medicamentos |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1597259B1 (es) |
| JP (1) | JP2006517551A (es) |
| KR (1) | KR20050100686A (es) |
| AR (1) | AR043154A1 (es) |
| AT (1) | ATE393769T1 (es) |
| AU (1) | AU2004212043A1 (es) |
| BR (1) | BRPI0407387A (es) |
| CA (1) | CA2514791A1 (es) |
| CO (1) | CO5690596A2 (es) |
| DE (1) | DE502004007000D1 (es) |
| HR (1) | HRP20050711A2 (es) |
| MA (1) | MA27734A1 (es) |
| MX (1) | MXPA05008288A (es) |
| NO (1) | NO20054208L (es) |
| PE (1) | PE20040949A1 (es) |
| PL (1) | PL377660A1 (es) |
| RS (1) | RS20050572A (es) |
| RU (1) | RU2005128499A (es) |
| TW (1) | TW200510417A (es) |
| WO (1) | WO2004072077A1 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040072831A1 (en) * | 2001-10-12 | 2004-04-15 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US8080657B2 (en) | 2001-10-12 | 2011-12-20 | Choongwae Pharma Corporation | Compounds of reverse turn mimetics and the use thereof |
| US7566711B2 (en) | 2001-10-12 | 2009-07-28 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7232822B2 (en) | 2001-10-12 | 2007-06-19 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7671054B1 (en) | 2001-10-12 | 2010-03-02 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7576084B2 (en) | 2001-10-12 | 2009-08-18 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| DE502004011328D1 (de) * | 2003-02-13 | 2010-08-12 | Sanofi Aventis Deutschland | Substituierte hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| DE102004042441A1 (de) * | 2004-08-31 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Mit Aminosäuren substituierte Hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2007003962A2 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| JP5102985B2 (ja) * | 2006-07-18 | 2012-12-19 | 東ソ−・エフテック株式会社 | 含フッ素２級アミン化合物の製造方法 |
| EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
| AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
| CL2008000017A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| JP2010514832A (ja) | 2007-01-04 | 2010-05-06 | プロシディオン・リミテッド | ピペリジンｇｐｃｒアゴニスト |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| RS52065B (en) | 2007-01-04 | 2012-06-30 | Prosidion Ltd | PIPERIDINSKI GPCR AGONIST |
| JP5204438B2 (ja) * | 2007-07-31 | 2013-06-05 | 東ソ−・エフテック株式会社 | 含フッ素アミン化合物の製造方法 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| EP2346871A1 (en) | 2008-10-14 | 2011-07-27 | PRISM BioLab Corporation | Alpha helix mimetics in the treatment of cancer |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| CN102482258B (zh) | 2009-05-07 | 2014-06-25 | 株式会社棱镜制药 | α-螺旋模拟物和与其相关的方法 |
| DK2470552T3 (en) | 2009-08-26 | 2014-02-17 | Sanofi Sa | NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2017223284A1 (en) | 2016-06-23 | 2017-12-28 | University Of Maryland, Baltimore | NON-CATALYTIC SUBSTRATE-SELECTIVE P38α-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF |
| JP2022511555A (ja) | 2018-12-07 | 2022-01-31 | ユニバーシティ オブ メリーランド，ボルチモア | 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤 |
| CN116406355A (zh) | 2020-05-18 | 2023-07-07 | Gen1E生命科学公司 | P38α促分裂原活化蛋白激酶抑制剂 |
| CN116367838A (zh) | 2020-10-29 | 2023-06-30 | Gen1E生命科学公司 | 结晶5-(二甲基氨基)-n-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物 |
| CN117120422A (zh) | 2021-03-23 | 2023-11-24 | Gen1E生命科学公司 | 取代的萘基P38α丝裂原活化的蛋白激酶抑制剂 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184223B1 (en) * | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| WO1998058947A1 (en) * | 1997-06-25 | 1998-12-30 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
| US6294525B1 (en) * | 1999-09-01 | 2001-09-25 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| DE502004011328D1 (de) * | 2003-02-13 | 2010-08-12 | Sanofi Aventis Deutschland | Substituierte hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
-
2004
- 2004-01-29 RU RU2005128499/04A patent/RU2005128499A/ru not_active Application Discontinuation
- 2004-01-29 EP EP04706145A patent/EP1597259B1/de not_active Expired - Lifetime
- 2004-01-29 RS YUP-2005/0572A patent/RS20050572A/sr unknown
- 2004-01-29 CA CA002514791A patent/CA2514791A1/en not_active Abandoned
- 2004-01-29 AU AU2004212043A patent/AU2004212043A1/en not_active Abandoned
- 2004-01-29 KR KR1020057014986A patent/KR20050100686A/ko not_active Application Discontinuation
- 2004-01-29 MX MXPA05008288A patent/MXPA05008288A/es not_active Application Discontinuation
- 2004-01-29 BR BR0407387-8A patent/BRPI0407387A/pt not_active IP Right Cessation
- 2004-01-29 AT AT04706145T patent/ATE393769T1/de not_active IP Right Cessation
- 2004-01-29 WO PCT/EP2004/000770 patent/WO2004072077A1/de active IP Right Grant
- 2004-01-29 JP JP2006501650A patent/JP2006517551A/ja active Pending
- 2004-01-29 DE DE502004007000T patent/DE502004007000D1/de not_active Expired - Lifetime
- 2004-01-29 PL PL377660A patent/PL377660A1/pl unknown
- 2004-02-11 PE PE2004000150A patent/PE20040949A1/es not_active Application Discontinuation
- 2004-02-11 AR ARP040100426A patent/AR043154A1/es unknown
- 2004-02-11 TW TW093103120A patent/TW200510417A/zh unknown
-
2005
- 2005-08-11 CO CO05079786A patent/CO5690596A2/es not_active Application Discontinuation
- 2005-08-11 MA MA28429A patent/MA27734A1/fr unknown
- 2005-08-12 HR HR20050711A patent/HRP20050711A2/xx not_active Application Discontinuation
- 2005-09-09 NO NO20054208A patent/NO20054208L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200510417A (en) | 2005-03-16 |
| EP1597259B1 (de) | 2008-04-30 |
| NO20054208L (no) | 2005-09-09 |
| JP2006517551A (ja) | 2006-07-27 |
| ATE393769T1 (de) | 2008-05-15 |
| AU2004212043A1 (en) | 2004-08-26 |
| KR20050100686A (ko) | 2005-10-19 |
| WO2004072077A1 (de) | 2004-08-26 |
| RS20050572A (en) | 2007-09-21 |
| PL377660A1 (pl) | 2006-02-06 |
| MXPA05008288A (es) | 2006-03-21 |
| PE20040949A1 (es) | 2005-01-12 |
| CA2514791A1 (en) | 2004-08-26 |
| EP1597259A1 (de) | 2005-11-23 |
| BRPI0407387A (pt) | 2006-02-07 |
| DE502004007000D1 (de) | 2008-06-12 |
| CO5690596A2 (es) | 2006-10-31 |
| MA27734A1 (fr) | 2006-02-01 |
| RU2005128499A (ru) | 2006-01-27 |
| HRP20050711A2 (en) | 2006-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR043154A1 (es) | Derivados sustituidos con nitrogeno de hexahidro-pirazino[1,2-a] pirimidin-4,7-diona, procedimientos para su preparacion y su uso como medicamentos | |
| AR043155A1 (es) | Derivados sustituidos de hexahidro-pirazino[1,2-a] pirimidin-4,7-diona, procedimientos para su preparacion y su uso como medicamentos | |
| PE20150400A1 (es) | Benzamidas n-sustituidas y su uso en el tratamiento del dolor | |
| ES2634634T3 (es) | Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9 (10)-dien-11-aciloxialquilenfenilo, procedimiento para su preparación y su uso para el tratamiento de enfermedades | |
| AR036586A1 (es) | Nuevas dihidro-pteridinonas, procedimientos para su preparacion, su utilizacion como medicamentos y las formulaciones farmaceuticas que las contienen | |
| AR083167A1 (es) | Derivados heterociclicos de benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, diabetes, obesidad y otras enfermedades neurologicas | |
| AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
| AR050610A1 (es) | Derivados de dihidropteridinona | |
| AR040700A1 (es) | Derivados de pirimidilsulfonamida como moduladores de receptores de quimioquinas | |
| AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
| AR097431A1 (es) | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim | |
| AR065015A1 (es) | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer | |
| BR112014025564B8 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma | |
| AR040514A1 (es) | Heterociclos diarilicos sustituidos, procedimiento para la preparacion de medicamentos y la utilizacion de los compuestos para tal fin | |
| AR050267A1 (es) | Derivados de urea ciclicos sustituidos con heterociclo, su preparacion y su uso farmaceutico como inhibidores de quinasa | |
| AR047516A1 (es) | Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico, procesos para su preparacion y su uso como medicamentos | |
| PE20110805A1 (es) | Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso | |
| AR064416A1 (es) | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR059484A1 (es) | Piridin-4-ilmetilamidas para combatir hongos patogenos | |
| AR064353A1 (es) | Compuestos y composiciones como inhibidores de la actividad del receptor cannabinoide 1. procesos de obtencion. | |
| AR068057A1 (es) | Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio. | |
| PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| AR084905A1 (es) | Derivados de 2,3-dihidro-furo[2,3-c]piridina, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por la activacion del receptor gpr119 acoplado a proteinas g | |
| AR039689A1 (es) | Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |